重组人生长激素治疗特发性矮小症对患儿血清p21 waf/cip1、瘦素水平及生长情况的影响  

Effect of recombinant human growth hormone as a treatment on serum p21 waf/cip1,leptin level and growth in children with idiopathic short stature

作　　者：马梦瑾 罗臻臻[1] 李志洁[1] Ma Mengjin;Luo Zhenzhen;Li Zhijie(Department of Community and Preventive Healthcare,Second Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan 450000,China)

机构地区：[1]郑州大学第二附属医院社区及预防保健科,河南郑州450000

出　　处：《中华生物医学工程杂志》2021年第3期311-314,共4页Chinese Journal of Biomedical Engineering

摘　　要：探究重组人生长激素治疗特发性矮小症(ISS)对患儿血清p21 waf/cip1、瘦素(LP)水平及生长情况的影响。114例ISS患儿随机分为常规治疗的对照组(n=57)和联合重组人生长激素治疗的观察组(n=57)。治疗12个月,两组血清IGF-1、IGFBP3、LP及身高、生长速度、预测成年身高均较治疗前升高,观察组高于对照组(P<0.05)。两组血清p21 waf/cip1 mRNA水平较治疗前降低,观察组低于对照组(P<0.05)。观察组不良反应率低于对照组(P<0.05)。重组人生长激素治疗ISS,可调节p21 waf/cip1和LP水平,促进生长发育,安全性高。To investigate the effects of recombinant human growth hormone(rhGH)as a treatment for idiopathic short stature(ISS)on serum p21 waf/cip1,leptin(LP)levels and growth in children.A total of 114 children with ISS were randomly divided into the control group on conventional treatment(n=57)and the study group receiving conventional treatment plus rhGH(n=57).After 12 months of treatment,serum IGF-1,IGFBP3,LP,height,growth rate,and predicted adult height in the two groups were higher than baseline,and were also higher in the study group than those in the control group(P<0.05);the level of serum p21 waf/cip1 mRNA in the two groups was lower than baseline,and was lower in the study group than that in the control group(P<0.05).The incidence of adverse reaction was lower in the study group compared with the control group(P<0.05).In conclusion,rhGH as a treatment of ISS can regulate the levels of p21 waf/cip1 and LP,promote growth and development,and is with high safety.

关 键 词：重组人生长激素 特发性矮小症 p21 waf/cip1 瘦素 身高 

分 类 号：R725.8[医药卫生—儿科]